Consistently, BLM treatment increased the mRNA level of tissue inhibitor of metalloproteinase-1, which plays a key role in scleroderma-associated fibrosis (19), and WKYMVm treatment reduced the BLM-induced expression of tissue inhibitor of metalloproteinase-1 (Figure S2A). The gene discussed is TIMP1; the disease is scleroderma.